Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Eli lilly and company crawled time : 07:00 save search
Top 5 Biopharma Companies Hiring Engineers
Published: 2024-01-25 (Crawled : 07:00) - biospace.com/
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -1.0%
H: 0.84%
C: 0.04%
companies biopharma
Viva Biotech's Portfolio Company DTx Pharma Reached the Acquisition Agreement with Novartis
Published: 2023-07-18 (Crawled : 07:00) - prnewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -0.04%
H: 1.43%
C: 0.95%
pharma acquisition novartis agreement
Roche announces collaboration with Lilly to enhance early diagnosis of Alzheimer's disease
Published: 2023-03-22 (Crawled : 07:00) - globenewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.21%
H: 1.15%
C: -0.24%
disease alzheimer's collaboration roche
Innovent Announces First Patient Dosed in a Phase 3 Clinical Trial (CLEAR) of Picankibart (Anti-IL23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Plaque Psoriasis
Published: 2023-02-16 (Crawled : 07:00) - biospace.com/
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -1.2%
H: 0.58%
C: -1.49%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -1.11%
H: 0.0%
C: 0.0%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: 0.16%
H: 0.29%
C: -1.56%
il23 trial psoriasis
Zealand Pharma Announces Appointment of David M. Kendall, M.D., as Chief Medical Officer
Published: 2022-06-02 (Crawled : 07:00) - globenewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -0.9%
H: 0.0%
C: 0.0%
ZEAL | $17.59 1.21% -4.21%
|
Health Technology
|
| O: -7.14%
H: 0.0%
C: -1.6%
MNKD | $4.15 0.97% 0.96% 1M
|
Health Technology
|
| O: -1.08%
H: 0.0%
C: 0.0%
pharma
Insulin Delivery Devices Market to Hit $39,371.8 Million Revenue by 2030, says P&S Intelligence
Published: 2022-03-18 (Crawled : 07:00) - prnewswire.com
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
|
| O: 0.66%
H: 0.0%
C: 0.0%
MDT | $81.29 0.89% 0.0% 5.2M
|
Health Technology
|
| O: 2.46%
H: 0.6%
C: 0.41%
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.12%
H: 1.93%
C: 0.63%
BDX | $234.36 0.21% 0.0% 800K
|
Health Technology
|
| O: 0.68%
H: 0.55%
C: 0.24%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.62%
H: 1.07%
C: 0.89%
PODD | $167.18 1.68% 1.65% 550K
|
Health Technology
|
| O: -0.35%
H: 5.54%
C: 5.11%
device liver intel insulin
BerGenBio and Oslo University Hospital Announce the AXL Inhibitor Bemcentinib will be Studied in the EU Funded EU-SolidAct trial in Hospitalised COVID-19 Patients
Published: 2022-01-27 (Crawled : 07:00) - prnewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.89%
H: 1.37%
C: -1.36%
covid-19 trial covid
Lilly's lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study
Published: 2021-12-21 (Crawled : 07:00) - prnewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.2%
H: 0.74%
C: 0.33%
atopic dermatitis dermatitis skin phase 3
UNION therapeutics and Innovent Biologics enter into strategic collaboration and license agreement for orismilast, a next-generation PDE4 inhibitor for inflammatory dermatology conditions
Published: 2021-09-28 (Crawled : 07:00) - prnewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -0.0%
H: 0.0%
C: -2.12%
collaboration license
Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials
Published: 2021-08-16 (Crawled : 07:00) - biospace.com/
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.33%
H: 2.03%
C: 1.91%
dermatitis phase 3 skin trial atopic dermatitis clearance
Innovent Announces the Establishment of the Scientific Advisory Board
Published: 2021-08-09 (Crawled : 07:00) - biospace.com/
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.33%
H: 3.2%
C: 0.98%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.97%
H: 0.23%
C: -0.18%
AnHeart and Innovent Releases Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting
Published: 2021-06-07 (Crawled : 07:00) - biospace.com/
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -0.01%
H: 15.52%
C: 10.16%
heart positive results trial
AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Receives FDA Emergency Use Authorization for COVID-19
Published: 2021-02-10 (Crawled : 07:00) - biospace.com/
ABCL | $3.985 -0.62% -0.63% 1.6M
|
|
| O: 12.77%
H: 0.06%
C: -11.34%
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 1.37%
H: 0.53%
C: -0.04%
covid fda antibody merge authorized covid-19 emergency use authorization
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.